Ipca Laboratories has recorded net profit growth of 9.8 per cent during the third quarter ended December 2010 to Rs.63.95 crore as against Rs.58.25 crore mainly on account of foreign exchange gain of Rs.11.21 crore as against a loss of Rs.1.65 crore. Its EBDITA remained almost same at Rs.91.22 crore. The net sales improved by 17.6 per cent to Rs.463.35 crore from Rs.393.92 crore. The board of directors has recommended second interim dividend of 50 per cent on equity share of Rs.2 each.


Its export income moved up by 26 per cent to Rs.253.66 crore from Rs.201.21 crore. Its total revenue from formulations business reached at Rs.344.63 crore from Rs.284.66 crore, representing a growth of 21 per cent. The total income from APIs improved by 9 per cent to Rs.118.72 crore as against Rs.109.22 crore. Revenue from Indian formulations business also increased by 12 per cent to Rs.177.50 crore from Rs.158.92 crore. Its exports from APIs improved by 9 per cent to Rs.118.72 crore from Rs.109.22 crore.


For the first nine months ended December 2010, Ipca's net sales increased by 17.9 per cent to Rs.1392 crore from Rs.1180 crore and is net profit moved up by 14.5 per cent to Rs.196.80 crore from Rs.171.90 crore in the similar period of last year. Its export income moved up by 20 per cent to Rs.715.51 crore from Rs.595.95 crore. Formulation revenue reached at Rs.1032 crore during the first three quarters and contributed 74 per cent of company's net sales. EPS worked out to Rs.15.69 as compared to Rs.13.75 in the last period.